

ASTRIA CONNECTION

Special Edition: February 2023

Introducing ...The ALPHA-STAR Trial!

We are pleased to announce the initiation of ALPHA-STAR trial, a clinical trial of STAR-0215 for people living with HAE.

The ALPHA-STAR trial is a proof-of-concept Phase 1b/2 trial evaluating single and multiple doses of STAR-0215 in people living with HAE types I and II. It is evaluating safety and tolerability, HAE attack rate, pharmacokinetics, pharmacodynamics, and quality of life in the enrolled participants. Over the next several months, Astria plans to work with Regulatory Authorities to open sites in the US, Canada, UK, and European countries.

Learn more about the ALPHA-STAR trial by visiting:

- ▶ [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT05695248) (NCT05695248)
- ▶ astriatx.com/alpha-star

About STAR-0215

STAR-0215 is an investigational monoclonal antibody inhibitor of plasma kallikrein with the potential to provide long-acting attack prevention for HAE with subcutaneous dosing (an injection given into the fatty tissue just under your skin using a small needle) once every three months or less frequently.

Stay in touch!

Sign up to receive our newsletters in your inbox:
<https://astriatx.com/for-patients/patient-newsletters/>

For advocacy questions: advocacy@astriatx.com

For questions about the ALPHA-STAR trial: 201study_general@astriatx.com

Follow us on social media: [@AstriaTx](#)



The information provided here is for those affected by HAE and caregivers. STAR-0215 is an investigational drug, which has not yet been authorized by government authorities for use other than in clinical trials.

